iRadimed (NASDAQ:IRMD – Get Free Report) and Beta Bionics (NASDAQ:BBNX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.
Valuation and Earnings
This table compares iRadimed and Beta Bionics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iRadimed | $83.81 million | 14.24 | $22.48 million | $1.83 | 51.01 |
| Beta Bionics | $100.25 million | 5.20 | -$73.20 million | ($1.51) | -7.75 |
Profitability
This table compares iRadimed and Beta Bionics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iRadimed | 27.36% | 24.48% | 21.25% |
| Beta Bionics | -60.27% | -23.00% | -20.55% |
Analyst Recommendations
This is a summary of recent ratings for iRadimed and Beta Bionics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iRadimed | 0 | 1 | 3 | 1 | 3.00 |
| Beta Bionics | 1 | 3 | 7 | 1 | 2.67 |
iRadimed presently has a consensus target price of $120.00, suggesting a potential upside of 28.54%. Beta Bionics has a consensus target price of $20.00, suggesting a potential upside of 70.79%. Given Beta Bionics’ higher probable upside, analysts plainly believe Beta Bionics is more favorable than iRadimed.
Risk & Volatility
iRadimed has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.29, meaning that its share price is 229% more volatile than the S&P 500.
Institutional & Insider Ownership
92.3% of iRadimed shares are owned by institutional investors. 36.8% of iRadimed shares are owned by company insiders. Comparatively, 5.3% of Beta Bionics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
iRadimed beats Beta Bionics on 10 of the 14 factors compared between the two stocks.
About iRadimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
